Inhibitex down on failed Phase III

On Monday, INHX fell $4.79 (66%) to $2.47 on 14.9 million shares after Veronate missed the primary endpoint of

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE